Dyslipidemia
Conditions
Keywords
Plant sterols, Low-Density Lipoprotein Cholesterol, Phytosterols
Brief summary
This is a randomized, double-blind, single-center, two-arm, placebo-controlled clinical trial that examine the effect of the consumption of a plant sterols-enriched low-fat milk. Half of the participants will consume of 1.5g of plant sterols daily as provided by two servings of the plant sterols-enriched low-fat milk product for 3 consecutive weeks, while the other half will consume placebo low-fat milk.
Detailed description
Plant sterols are the naturally occurring functional equivalent of mammalian cholesterol. Plant sterols differ structurally from cholesterol by a methyl or ethyl group in their side chains and are not synthesized by the human body. These structural differences render them minimally absorbable in the intestine. It has been consistently reported that dietary incorporation of plant sterols(1.5-2 g/day) reduces serum low-density lipoprotein cholesterol (LDL-C) levels with minimal adverse events. The hypochoelsterolemic effects of plant sterols is explained by an inhibition of cholesterol absorption, which is ascribed to a competition with intestinal cholesterol for incorporation into mixed micelles, although other possible mechanistic explanation have been proposed.
Interventions
DIETARY_SUPPLEMENTPlant sterols-enriched low-fat milk
The study product is a dried partly skimmed milk powder with no more than 12% milk fat (11.4g total fat/100g product) containing unesterified, unhydrogenated plant sterols.
DIETARY_SUPPLEMENTLow-fat milk
The placebo product is a dried partly skimmed milk powder.
Sponsors
The University of Hong Kong
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Southern Chinese male or female ≥ 18years. * In good general health as evidenced by medical history * Have the ability to understand the requirements of the study, provide written informed consent, including consent for the use and discloser of research-related health information, and comply with the study data collection procedures. Provide signed and dated informed consent form
Exclusion criteria
* Subject with familial hypercholesterolemia * Ingestion of drugs known to interfere with lipid profiles, such as hormone replacement treatment, diuretics, beta-blockers, statin or other hypochoelsterolemic drug treatment * Smoking \> 10 cigarettes/day * Subject with heavy alcohol intake (Alcohol \> 3 glasses wine, or 2 beers, or 1 shot hard alcohol/day) * Having milk intolerance or dislike * Having major diseases such as diabetes (type I and type II), renal or liver diseases * Subject presenting known allergy or hypersensitivity to milk proteins, soy and peanut * Subject refusing to stop the consumption of plant sterols-enriched products if any during the study (other than the studied product) * Subject receiving systemic treatment or topical treatment likely to interfere with evaluation of the study parameters * Subject currently involved in a clinical trial or in an exclusion period following participation in another clinical trial * Pregnancy or lactation * Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean of serum low-density lipoprotein cholesterol (LDL-C) | From baseline to week 3 |
Secondary
| Measure | Time frame |
|---|---|
| Change of high-density lipoprotein cholesterol (HDL-C) | From baseline to week 3 |
| Change of total cholesterol | From baseline to week 3 |
| Change of serum LDL-C | From baseline to week 3 |
| Change of serum creatinine | From baseline to week 3 |
| Changes of fasting blood glucose | From baseline to week 3 |
| Change of triglycerides (TAG) | From baseline to week 3 |
Outcome results
None listed